A result can be statistically significant and still barely matter — or matter enormously and just miss significance. Learning to tell the difference is one of the most useful skills for reading research well.

The path from a promising finding in the lab to a proven human therapy is long by design. Understanding why makes you a sharper — and more patient — reader of early science.

In a single day, the FDA told multiple peptide sellers that an RUO label does not control when the surrounding evidence establishes an intended human-drug use. The reasoning is worth reading closely.

Oral versus injectable, local versus systemic, short cycle versus long — BPC-157 has some of the most elaborate community conventions of any peptide, built almost entirely on animal data and repetition rather than human trials.

By engaging three metabolic receptors at once — GLP-1, GIP, and glucagon — retatrutide represents a genuinely new idea in metabolic pharmacology. Here is what triple agonism means, and what the human data shows so far.

Intermittent schedules, exercise timing, and the mixture of animal research, mechanistic reasoning, and repetition that shaped today's community conventions.

Elamipretide is now an approved drug for one rare disease at a specific dose — yet the longevity community researches it at very different, usually lower amounts. The gap between the label and the practice is the story.

If mitochondrial decline sits near the center of aging, the interesting question is how researchers are trying to address it. The research splits into three distinct strategies — protect the structure, restore the metabolic inputs, and strengthen the signals — and seeing them together is the best map of the field.

The peptide world's most familiar growth-hormone pairing runs on a specific logic: two receptors, complementary signaling, and a nightly ritual built largely outside controlled trials.

Tesamorelin is unusual: an FDA-approved drug with a defined regimen and real trial data, used by the community for a different, off-label goal. Comparing the label with the practice is where this one gets interesting.

They are often mentioned in one breath, but the peptides that raise growth hormone work through genuinely different mechanisms — and the differences matter. A guide to the growth hormone axis and the molecules that act on it.

For most of its history, medicine has managed disease from the outside. A cluster of technologies now lets us edit, engineer, and reprogram biology directly — moving from treating symptoms toward rewriting the systems beneath them.

Biology is entering an era in which molecules, computation, and engineering are converging to answer questions that once belonged to science fiction. A look at where the real frontier is.